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1. Introduction 
Levocetirizine dihydrochloride (LEV), (2-[4-[(R)-(4-
chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid 
dihydrochloride) (Figure 1) is a third generation non sedative 
antihistamine, and is the active enantiomer of cetirizine 
dihydrochloride.[1] 
LEV has the advantages of higher efficacy, less side effects, and 
longer duration over other antihistamines, and has begun to replace 
cetirizine in clinical therapy stepwise. It has been chemically proved that 
the half dosage form of LEV (2.5 mg) has comparable antihistaminic 
activity to normal amount (5.0 mg) of cetirizine in the treatment of 
allergic rhinitis and chronic idiopathic urticarial.[2] 
 
 
 
Figure 1: Chemical structure of Levocetirizine dihydrochloride 
 
Montelukast is an oral selective leukotriene receptor 
antagonist that inhibits the cysteinyl leukotriene cysLT1 and has been 
shown to be effective in the treatment of chronic asthma and Chemically, 
it is2-[1-[(R)-[3-[2(E)-(7-chloroquinolin-2- yl)vinyl] phenyl]-3-[2-(1-
hydroxy-1- methylethyl)phenyl]propyl -sulfanylmethyl] cyclopropyl] 
acetic acid sodium salt (Figure 2).[3] 
 
 
 
Figure 2: Chemical structure of Montelukast sodium 
 
Literature reveals that various methods have been reported 
for analysis of Levocetirizine dihydrochloride and montelukast sodium in 
single component formulations but a less number of methods are 
available for the simultaneous estimation of these two drugs in 
multicomponant dosage forms.[4-9] Thus, the objective of this work was 
to develop an accurate, specific, repeatable and validated HPLC method 
according to ICH guidelines[10] for simultaneous determination of 
Levocetirizine dihydrochloride and Montelukast Sodium in tablet dosage 
form. 
 
2. Materials and methods  
2.1 HPLC–PDA instrumentation and chromatographic conditions  
The HPLC system was an LC Waters (Waters, Milford, MA, 
USA) consisting of quaternary gradient system (600 Controller), in line 
degasser (Waters, model AF), photodiode array detector (Water, 2998 
model) and auto sampler (Waters, model 717 plus). Data was processed 
using Empower Pro software (Waters, Milford, MA, USA). 
Chromatographic separation assay was performed with a Water’s C-18 
analytical column (150 mm × 4.6 mm inner diameter, 5  μm particle size, 
Waters, Dublin, Ireland) maintained at ambient temperature. The mobile 
Abstract 
A simple, selective and sensitive reverse phase high performance liquid 
chromatography (Rp-HPLC) method has been proposed for the simultaneous quantitative 
determination of levocetirizine dihydrochloride (LEV) and Montelukast sodium (MON) in pure 
form as well as in its pharmaceutical formulation. The chromatography was carried out on 
Waters C18 analytical column (15cm × 4.6 mm, 5µ) using a mobile phase of methanol: water 
(75:25 v/v). The flow rate was 1.0 ml/min with detection at 235 nm. The retention time of LEV 
and MON were found to 2.88 and 3.83 min respectively. The linearity for LEV and MON were in 
the range of 50-150 µg/mL and 100- 300 µg/mL respectively. The recoveries of LEV and MON 
were found to be 100.00% and 99.00%, respectively. The proposed method was validated and 
successfully applied to the estimation of LEV and MON in combined tablet dosage forms. 
 
B. Mohammed Ishaq et al/ Rp-HPLC Method for Simultaneous Estimation of Levocetirizine Dihydrochloride and Montelukast Sodium in tablets 
 
© ASD Publisher All rights reserved.                                                                                                                                                                                                                       19 
phase was pumped at a flow rate of 1.0 mL min−1. The detection 
wavelength was 235 nm.  
2.2 Chemical and reagents 
Pure powder (>99.9% purity) of LEV and MON was supplied as 
a gift sample by Hetero drugs Pvt. Ltd., Hydrabad. The tablet Dosage form 
of LEV and MON was purchased from Anukar Pharmacy, Hyderabad. 
HPLC grade acetonitrile (ACN) were purchased from Scharlau 
(Sentmenat, Spain). HPLC grade water was obtained by distilling 
deionised water produced by a Milli-Q millipore water system (Milford, 
MA, USA).  All the other reagents and materials were of analytical grade 
and supplied from commercial sources. The aqueous and organic 
components of the mobile phase were mixed and degassed under 
vacuum by the HPLC. The LC mobile phases were filtered through 0.2 μm 
cellulose acetate membrane filters (Sartorius Ste-dim Biotech S.A., 
Aubagne Cedex, France) with a solvent filtration apparatus. 
2.3 Mobile phase 
A mixture of methanol: water in the ratio of 75:25 %v/v was 
used as mobile phase. Mixed solvents were filtered through 0.2 μm 
cellulose acetate membrane filters (Sartorius Ste-dim Biotech S.A., 
Aubagne Cedex, France) with a solvent filtration apparatus, degassed and 
used as mobile phase. Same was used as diluents for the preparation of 
drug solutions. 
2.4 Standard and sample solutions 
Stock solution of LEV was prepared by dissolving 10 mg of LEV 
in a 10 ml volumetric flask, and the volume is made up with the diluent. 
Subsequent dilutions of this solution ranging from 50 to 150 µg/ ml were 
made with the diluent. 20 mg of MON was dissolved in 10 ml volumetric 
flask and the volume was made up with the diluents. Subsequent 
dilutions of this solution ranging from 100 to 350 µg/ ml were made with 
the diluent. Working solutions were prepared daily from the stock 
solutions. The containers used for storage were screw-capped tubes 
coated externally by aluminium foil. 
2.5 Assay of pharmaceutical preparation:  
To carry out the sample solution, 20 tablets were taken and 
weighed individually, obtaining afterwards the average weight of these 
tablets, finally they were ground. An appropriate portion of this powder, 
equivalent to 10 mg of LEV was weighed and placed in a 10ml volumetric 
flask, dissolving it in the mobile phase. This solution was sonicated for 10 
min to dissolve and remove the entire active from the tablet. The solution 
was filtered if necessary. 5 ml of aliquot was taken and transferred to 
volumetric flask of 50 ml capacity and volume was made up to the mark 
with the diluent. This solution was used for the estimation of LEV and 
MON (100μg/ml). 
 
3. Results and Discussion 
Estimation of LEV and MON in tablet dosage forms by RP-HPLC 
method was carried out using optimized chromatographic conditions. 
The typical chromatogram of standard and sample solution is given in 
Figure 3 and Figure 4 respectively. The peak area ratio of standard and 
sample solutions was calculated. The results of analysis shows that the 
amounts of drugs were in good agreement with the label claim of the 
formulations.  
 
 
Figure 3: Typical chromatogram of standard sample of LEV and MON 
 
Figure 4: Typical chromatogram of tablet sample of LEV and MON 
 
Optimization of mobile phase was performed based on 
resolution, asymmetric factor and peak area obtained for both LEV and 
MON. The mobile phase composed of a mixture of methanol: water in the 
ratio of 75: 25 v/v was found to be satisfactory and gave two symmetric 
and well-resolved peaks for LEV and MON. The summary of optimized 
chromatographic conditions was shown in table-1. The retention time of 
levocetirizine dihydrochloride and Montelukast sodium was found to be 
2.88± 0.2 min and 3.83± 0.2 min respectively. The total time of analysis 
was less than 6 minutes. Results showed an excellent correlation 
between response factor and concentration of drugs within the 
concentration range. 
Table 1: Optimized HPLC conditions for simultaneous estimation of 
Rosuvastatin and Ezetimibe 
S. No Parameter Description/Value 
1. Stationary Phase Water’s C18 (250X4.6X5) 
2 Mobile Phase Methanol: water 75:25 v/v 
3 Flow rate 1.0  ml/min 
4 Detection Wavelength 235 nm 
5 Detector Photo diode array 
6 Injection autosampler -Waters, model 717 plus 
7 Rt’s 
Levocetirizine: 2.88 min 
Montelukast: 3.83 min 
8 Injection volume 10 μl 
9 Column Temperature 40 °C 
10 Run time 7 mins 
11 Diluent Mobile Phase 
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The calibration curve for LEV was obtained by plotting the 
peak area of LEV versus the concentration of LEV over the range of 50-
150 μg/mL, and it was found to be linear with r2 = 0.9991. Similarly, the 
calibration curve for MON was obtained over the range of 100-300 
μg/mL and was found to be linear with r2 = 0.9994. The data of 
regression analysis of the calibration curves are shown in (Table-2). The 
detection limit for LEV and MON were 0.4 ng/mL and 0. 1ng/mL, 
respectively. The quantitation limit for LEV and MON were 0.36ng/mL 
and 0.12ng/ml, respectively, which suggest that a nano gram quantity of 
both the compounds can be estimated accurately. The validation 
parameters are summarized in (Table-2). 
The recoveries of LEV and MON were found to be 99.0 % and 
100.00%, respectively. The system suitability test parameters are shown 
in (Table-2). The liquid chromatographic method was applied to the 
determination of LEV and MON in their combined dosage forms. 
 
Table 2: Summary of validation Results 
 
S. No. Validation parameter 
Results 
Levocetirizine Montelukast 
1.  Linearity 50-150µg/ml 100-300 µg/ml 
2.  Regression equation (y) y = 95579x + 98597 y = 128494x + 127999 
3.  Regression coefficient (r2) R² = 0.9991 R² = 0.9994 
4.  Limit of detection (μg/mL) 0.42 ng/mL 0. 16 ng/mL 
5.  Limit of quantitation (μg/mL) 0.36 ng/mL 0.12 ng/ml 
6.  Accuracy (Mean % recovery)* 99 % 100 % 
7.  
Precision (%RSD) 
Intra-day precision (%RSD)* 0.19 0.18 
Inter-day precision (%RSD)* 0.41 0.24 
8.  Mean Assay (% Purity) 100 99 
9.  Tailing factor 0.968 0.920 
10.  Number of theoretical plates 5697 6484 
11.  Resolution 3.1 
* Replicates of three concentration levels (in three determinations); ** Ten repetitive injections of same homogeneous sample. All the values were 
expressed in mean± SD. 
 
4. Conclusion 
Proposed study describes a new RP-HPLC method for the 
estimation of LEV and MON combination in mixture using simple mobile 
phase compared to the reported method. The method gives good 
resolution between both the compounds with a short analysis time (<7 
min). The method was validated and found to be simple, sensitive, 
accurate and precise. Percentage of recovery shows that the method is 
free from interference of the excipients used in the formulation. 
Therefore, the proposed method can be used for routine analysis of LEV 
and MON in their combined dosage form. 
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